Découvrez les Meilleures Cliniques et Coûts des traitements de cancer de la vessie en Italie 2024

Dr Braun's primary responsibilities include direct leadership and execution of complex surgeries, including gastric bypass, sleeve gastrectomy, and other advanced metabolic and bariatric procedures. He has developed solid experience in managing the different clinical challenges present in obese patients, providing them with personalized and optimized care to ensure positive long-term outcomes.His surgical practice is based on an in-depth methodology and a careful look at the latest technological innovations in the field of bariatric surgery. He has actively worked to implement advanced protocols and continually improve operational techniques, while maintaining the highest standards of patient safety and care.With over 2000 operations performed as a surgeon specializing in oncology, he has developed extensive experience and expertise in laparoscopic and robotic surgery applied to the care of cancer patients.As a primary operator, he has successfully conducted a wide range of laparoscopic and robotic surgeries for the treatment of oncological conditions, including gastrointestinal, urological, gynecological and other solid tumors. His surgical practice has focused on the application of advanced techniques, using cutting-edge laparoscopic instruments and robotic systems

Le professeur Montorsi est l'un des meilleurs experts italiens en urologie et andrologie. Détient de nombreux prix scientifiques. Dirige l'Institut de Recherche Urologique (URI) en Italie. Reconnu parmi les chercheurs les plus influents de la dernière décennie. Spécialité Le professeur Montorsi propose des traitements du cancer de la vessie, de la prostate et du rein à l'aide de techniques chirurgicales mini-invasives et de robots. A réalisé plus de 8 000 chirurgies d'urologie et d'andrologie. A développé sa méthode de patch veineux pour corriger le dysfonctionnement veineux occlusif. L'expérience professionnelle Depuis 2013 — Directeur Scientifique de l'Institut Scientifique San Raffaele (Italie) Directeur de l'Institut de Recherche Urologique (URI) du Département d'Urologie de l'Université Vita-Salute San Raffaele de Milan Éducation   1987 — Faculté de Médecine de l'Université de Milan — Diplôme en médecine et chirurgie 1992 — Faculté de Médecine de l'Université de Milan — Spécialité en urologie 2017 — Collège royal des chirurgiens d'Angleterre — Bourse d'honneur. Prix 1998 — Prix Crystal Matula de l'Association européenne d'urologie en tant que meilleur urologue européen de moins de 40 ans 2016 — Commandeur de l'Ordre du mérite de la République italienne 2018 — Prix Hugh Hampton Young de l'American Urological Association pour ses contributions exceptionnelles à la science de l'urologie et de l'oncologie urologique (le Dr Montorsi est le premier non-américain à recevoir ce prix) 2019 — Le Frans Debruyne Lifetime Achievement Award de l'Association européenne d'urologie pour sa contribution exceptionnelle au développement de l'association. Activité scientifique Le professeur Montorsi a rédigé plus de 1 000 articles. Le Web Science Group a inclus le docteur dans la liste des chercheurs les plus influents de la dernière décennie. Activité d'enseignement Depuis 2012 — Directeur de l'École d'Urologie — Université Vita-Salute San Raffaele (Italie) 2008-2012 — Professeur d'urologie — Université Vita-Salute San Raffaele (Italie) 2002-2008 — Professeur agrégé d'urologie — Université Vita-Salute San Raffaele (Italie). Adhésion à des organisations L'Association des urologues universitaires européens (AAEU) L'Association américaine des chirurgiens génito-urinaires L'Association américaine d'urologie La société d'endourologie L'Association Européenne d'Urologie La Société Européenne de Médecine Sexuelle (ESSM) La Société Italienne d'Andrologie (SIA) La Société italienne d'urologie.

Prof. Deraco has dedicated his career to helping patients with complex cancers, particularly those affecting the peritoneum, a membrane in the abdomen. He began his medical career in 1989 at the Surgery and Experimental Oncology Departments of the Fondazione IRCCS, National Cancer Institute in Milan, Italy. Over the years, he has played a key role in advancing treatments for peritoneal surface malignancies (PSM). For more than a decade, he was the lead physician for the Peritoneal Surface Malignancies Program. Since 2017, he has served as the director of the Peritoneal Surface Malignancies Unit, where he continues to focus on providing cutting-edge care for his patients.Prof. Deraco’s expertise is in specialized cancer treatments like Cytoreductive Surgery (CRS), Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC), and Pressurized Intra-Peritoneal Aerosolized Chemotherapy (PIPAC). These techniques aim to remove cancer and deliver heated chemotherapy directly to the abdomen, giving patients with PSM new hope. He has successfully treated over 1,200 patients using these advanced methods.In addition to his clinical work, Prof. Deraco is a professor at Milan University, where he teaches future surgeons about peritoneal surface malignancies. His teaching extends internationally, as he has mentored over 30 postdoctoral fellows from prestigious institutions worldwide.Prof. Deraco’s educational background is extensive. He earned his medical degree from the University of Messina in 1987 with top honors, followed by a specialization in general surgery five years later. His training continued in Paris, where he specialized in oncology at the prestigious Paris Dauphine University. He further honed his skills through fellowships in world-renowned institutions such as the Gustave Roussy Institute in France, the Royal Marsden Hospital in the UK, and the Washington Cancer Institute in the USA.Throughout his career, Prof. Deraco has remained actively involved in research and professional organizations. He has published over 250 scientific articles and 25 book chapters, contributing to the advancement of cancer treatment globally. He serves on the board of multiple scientific societies dedicated to cancer research, including the Peritoneal Surface Oncology International Group (PSOGI) and the Italian Society for Loco-Regional Cancer Therapy (SITILO).